Revolutionizing Treatment: Immix Biopharma Speeds Up Enrollment for Groundbreaking AL Amyloidosis Trial with NXC-201 CAR-T
Revolutionizing Treatment: Immix Biopharma Speeds Up Enrollment for Groundbreaking AL Amyloidosis Trial with NXC-201 CAR-T Immix Biopharma Successfully Completes Phase 1b Segment LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL